LivaNova PLC
LIVN
View Detailed Chart
55.000USD
-0.910-1.63%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
3.00BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-1.63%
5 Days
-2.17%
1 Month
+2.84%
6 Months
+34.67%
Year to Date
+18.76%
1 Year
+7.36%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-19Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
10
analysts
Buy
Current Rating
63.632
Target Price
+13.81%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, Neuromodulation and Advanced Circulatory Support (ACS). Cardiopulmonary segment is engaged in the design, development, manufacture, marketing and selling of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula and other related accessories. It includes the Essenz Perfusion System, the Company’s next-generation HLM with an embedded patient monitor for tailored patient care strategies. Neuromodulation segment is engaged in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). The ACS segment is engaged in the development, production, and sale of temporary life support products.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 22.67% year-on-year.
Fairly Valued
The company’s latest PE is -14.22, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 56.85M shares, decreasing 10.89% quarter-over-quarter.
Held by PRIMECAP Management
Star Investor PRIMECAP Management holds 4.64M shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, Neuromodulation and Advanced Circulatory Support (ACS). Cardiopulmonary segment is engaged in the design, development, manufacture, marketing and selling of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula and other related accessories. It includes the Essenz Perfusion System, the Company’s next-generation HLM with an embedded patient monitor for tailored patient care strategies. Neuromodulation segment is engaged in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). The ACS segment is engaged in the development, production, and sale of temporary life support products.
Ticker SymbolLIVN
CompanyLivaNova PLC
CEOMr. Vladimir A. Makatsaria
Websitehttps://www.livanova.com/
Related Instruments
+1.09%
-0.27%
-0.53%
-0.28%
-0.71%
+0.10%
-0.69%
-10.99%
-0.69%
-0.80%
-0.12%
-0.05%
-0.49%
+1.41%
-0.87%
-2.83%
-0.83%
-0.89%
-1.01%
+0.33%
